Scaffold-mediated delivery for non-viral mRNA vaccines

Abstract

mRNA is increasingly being recognized as a promising alternative to pDNA in gene vaccinations. Only recently, owing to the needs of cancer immunotherapies, has the biomaterials/gene delivery community begun to develop new biomaterial strategies for immunomodulation. Here, we report a novel way to use implantable porous scaffolds as a local gene delivery depot to enhance mRNA vaccine immunization in vitro, and in vivo when compared with conventional bolus injections. We first evaluated transfection efficiencies of single-stranded mRNA condensed and charge neutralized with two lipids (Lipofectamine Messenger MAXTM LM-MM and StemfectTM SF) and two cationic polymers (in vivo-jetPEI™, Poly (β-amino ester)) as gene carriers. As SF demonstrated highest in vitro transfection and cell viability, it was selected for subsequent porous polymer scaffold-loading trials. Enhanced in vitro transfection of SF:mRNA nanoparticle-loaded poly (2-hydroxyethyl methacrylate) (pHEMA) scaffolds was also observed with a DC2.4 cell line. Improved sustained local release and local transgene expression were also demonstrated with SF:mRNA nanoparticle-loaded pHEMA scaffolds in vivo compared with bolus injections. Our results suggest that mRNA polyplex-loaded scaffolds may be a superior alternative to either repeated bolus immunizations or ex vivo transfection cell immunotherapies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded rna via toll-like receptor 7 and 8. Science. 2004;303:1526–9.

  2. 2.

    Diebold SS, Kaisho T, Hemmi H, Akira S, Reis E, Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529–31.

  3. 3.

    Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature. 2001;413:732–8.

  4. 4.

    Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. 2011;34:1–15.

  5. 5.

    Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. J Control Release. 1999;60:149–60.

  6. 6.

    Yamamoto A, Kormann M, Rosenecker J, Rudolph C. Current prospects for mRNA gene delivery [Internet]. Eur J Pharm Biopharm. 2009;71:484–9.

  7. 7.

    Gao Y, Huang J-Y, O’Keeffe Ahern J, Cutlar L, Zhou D, Lin F-H, et al. Highly branched Poly(β-amino esters) for non-viral gene delivery: high transfection efficiency and low toxicity achieved by increasing molecular weight. Biomacromolecules. 2016;17:3640–7.

  8. 8.

    Koo H, Jin Gwoo, Kang H, Lee Y, Nam HY, Jang Hsuk, et al. A new biodegradable crosslinked polyethylene oxide sulfide (PEOS) hydrogel for controlled drug release. Int J Pharm. 2009;374:58–65. Jun 5

  9. 9.

    Persano S, Guevara ML, Li Z, Mai J, Ferrari M, Pompa PP, et al. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials. 2017;125:81–9.

  10. 10.

    Su X, Fricke J, Kavanagh DG, Irvine DJ. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol Pharm. 2011;8:774–87.

  11. 11.

    Phua KKL, Leong KW, Nair SK. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. J Control Release. 2013;166:227–33.

  12. 12.

    Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater. 2017;2:17056.

  13. 13.

    Xie Y, Yang ST, Kniss DA. Three-dimensional cell-scaffold constructs promote efficient gene transfection: implications for cell-based gene therapy. Tissue Eng. 2001;7:585–98.

  14. 14.

    Jang J-H, Bengali Z, Houchin TL, Shea LD. Surface adsorption of DNA to tissue engineering scaffolds for efficient gene delivery. J Biomed Mater Res Part A. 2006;77A:50–8.

  15. 15.

    O’Rorke S, Keeney M, Pandit A. Non-viral polyplexes: scaffold mediated delivery for gene therapy. Prog Polym Sci. 2010;35:441–58.

  16. 16.

    Kim YM, Park MR, Song SC. Injectable polyplex hydrogel for localized and long-term delivery of siRNA. ACS Nano. 2012;6:5757.

  17. 17.

    Wang LL, Burdick JA. Engineered hydrogels for local and sustained delivery of RNA-interference therapies. Adv Healthc Mater. 2017;6:62017.

  18. 18.

    Nguyen K, Dang PN, Alsberg E. Functionalized, biodegradable hydrogels for control over sustained and localized siRNA delivery to incorporated and surrounding cells. Acta Biomater. 2013;9:4487.

  19. 19.

    Ma Z, Yang C, Song W, Wang Q, Kjems J, Gao S. Chitosan hydrogel as siRNA vector for prolonged gene silencing. J Nanobiotechnol. 2014;12:23.

  20. 20.

    Stachowiak AN, Irvine DJ. Inverse opal hydrogel-collagen composite scaffolds as a supportive microenvironment for immune cell migration. J Biomed Mater Res Part A. 2008;85:815–28.

  21. 21.

    Shea LD, Smiley E, Bonadio J, Mooney DJ. DNA delivery from polymer matrices for tissue engineering. Nat Biotechnol. 1999;17:551–4.

  22. 22.

    Ali OA, Mooney DJ. Sustained GM-CSF and PEI condensed pDNA presentation increases the level and duration of gene expression in dendritic cells. J Control Release. 2008;132:273–8.

  23. 23.

    Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ. Infection-mimicking materials to program dendritic cells in situ. Nat Mater. 2009;8:151–8.

  24. 24.

    Zhang X, Li Y, Chen YE, Chen J, Ma PX. Cell-free 3D scaffold with two-stage delivery of miRNA-26a to regenerate critical-sized bone defects. Nat Commun. 2016;7:10376. Jan 14

  25. 25.

    Badieyan ZS, et al. Transcript-activated collagen matrix as sustained mRNA delivery system for bone regeneration. J Control Release. 2016;239:137–48.

  26. 26.

    Zaitseva TS, et al. Aligned nanofibrillar scaffolds for controlled delivery of modified mRNA. Tissue Eng Part A. 2018; https://doi.org/10.1089/ten.TEA.2017.0494.

  27. 27.

    Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 2000;60:0008–5472.

  28. 28.

    Sunshine J, Green JJ, Mahon KP, Yang F, Eltoukhy AA, Nguyen DN, et al. Small-molecule end-groups of linear polymer determine cell-type gene-delivery efficacy. Adv Mater. 2009;21:4947–51.

  29. 29.

    Marshall AJ, Ratner BD. Quantitative characterization of sphere-templated porous biomaterials. AIChE J. 2005;51:1221–32.

  30. 30.

    Anchordoquy TJ, Carpenter JF, Kroll DJ. Maintenance of transfection rates and physical characterization of lipid/DNA complexes after freeze-drying and rehydration. Arch Biochem Biophys. 1997;348:199–206.

  31. 31.

    Inoh Y, Nagai M, Matsushita K, Nakanishi M, Furuno T. Gene transfection efficiency into dendritic cells is influenced by the size of cationic liposomes/DNA complexes. Eur J Pharm Sci. 2017;102:230–6.

  32. 32.

    Chen R, Ma H, Zhang L, Bryers JD. Precision-porous templated scaffolds of varying pore size drive dendritic cell activation. Biotechnol Bioeng. 2018; 115: 1086–95.

  33. 33.

    Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest. 2000;106:1065–9. Nov

  34. 34.

    Bettinger T, Carlisle RC, Read ML, Ogris M, Seymour LW. Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Res. 2001;29:3882–91.

  35. 35.

    Rejman J, Tavernier G, Bavarsad N, Demeester J, De Smedt SC. MRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. J Control Release. 2010;147:385–91.

  36. 36.

    Uchida S, Itaka K, Chen Q, Osada K, Ishii T, Shibata MA, et al. PEGylated polyplex with optimized PEG shielding enhances gene introduction in lungs by minimizing inflammatory responses. Mol Ther. 2012;20:1196–203.

  37. 37.

    Yadava P, Gibbs M, Castro C, Hughes JA. Effect of lyophilization and freeze-thawing on the stability of siRNA-liposome complexes. AAPS PharmSciTech. 2008;9:335–41.

  38. 38.

    Hosseinkhani H, Hosseinkhani M, Gabrielson NP, Pack DW, Khademhosseini A, Kobayashi H. DNA nanoparticles encapsulated in 3D tissue-engineered scaffolds enhance osteogenic differentiation of mesenchymal stem cells. J Biomed Mater Res Part A. 2008;85:47–60.

  39. 39.

    Ow-Sullivan MM, Green JJ, Przybycien TM. Development of a novel gene delivery scaffold utilizing colloidal gold-polyethylenimine conjugates for DNA condensation. Gene Ther. 2003;10:1882–90.

  40. 40.

    Raftery RM, Tierney EG, Curtin CM, Cryan SA, O’Brien FJ. Development of a gene-activated scaffold platform for tissue engineering applications using chitosan-pDNA nanoparticles on collagen-based scaffolds. J Control Release. 2015;210:84–94.

  41. 41.

    Capan Y, Woo BH, Gebrekidan S, Ahmed S, DeLuca PP. Preparation and characterization of poly (D,L-lactide-co-glycolide) microspheres for controlled release of poly(L-lysine) complexed plasmid DNA. Pharm Res. 1999;16:509–13.

  42. 42.

    Hosseinkhani H, Azzam T, Kobayashi H, Hiraoka Y, Shimokawa H, Domb AJ, et al. Combination of 3D tissue engineered scaffold and non-viral gene carrier enhance in vitro DNA expression of mesenchymal stem cells. Biomaterials. 2006;27:4269–78.

  43. 43.

    Pannier AK, Segura T. Surface-and hydrogel-mediated delivery of nucleic acid nanoparticles. Methods Mol Biol. 2013;948:149–69.

Download references

Acknowledgements

This work was supported by the National Institutes of Health/NIAID (5R01AI074661 and 2R56AI074661-06).

Author information

Ruying Chen designed and executed the study, analyzed and interpreted the data, and drafted and revised the manuscript. Hong Zhang executed the PBAE study, interpreted the data, and revised the manuscript. Jingxuan Yan executed portions of the study, interpreted the data, and revised the manuscript.

Correspondence to James D. Bryers.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Supplemental Information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading